Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | OTC | P00480 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169670 | 1.00 | DPP7 (0.44) | DPP7OTCDDAH1GNAI3GNAO1 | |
| SCHEMBL18866881 | 1.00 | DPP7 (0.44) | DPP7OTCDDAH1GNAI3GNAO1 | |
| Succinic Acid SCHEMBL28261408 | 0.91 | OTC (0.41) | DPP7OTCDDAH1ARG1C3AR1 | |
| L-Citrulline SCHEMBL20587 | 0.85 | OTC (0.59) | OTCDDAH1ARG1GSRCYP1A2 | |
| SCHEMBL20951925 | 0.85 | OTC (0.46) | DPP7OTCDDAH1GNAI3GNAO1 | |
| L-Citrulline SCHEMBL15909604 | 0.85 | OTC (0.59) | OTCDDAH1ARG1GSRCYP1A2 | |
| L-Citrulline SCHEMBL9070200 | 0.85 | OTC (0.59) | OTCDDAH1ARG1GSRCYP1A2 | |
| L-Citrulline SCHEMBL22426116 | 0.85 | OTC (0.59) | OTCDDAH1ARG1GSRCYP1A2 | |
| L-Citrulline SCHEMBL4542892 | 0.85 | OTC (0.59) | OTCDDAH1ARG1GSRCYP1A2 | |
| L-Citrulline SCHEMBL437142 | 0.85 | OTC (0.59) | OTCDDAH1ARG1GSRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118950437-A | Photoelectric material based on ultrathin protein nano film, and preparation method and application thereof | 陕西师范大学 | 2024-11-15 | — | — | CN | claimed |
| CN-118844429-A | Protein-based agricultural chemical with reduced and enhanced efficacy | 陕西师范大学 | 2024-10-29 | — | — | CN | claimed |
| EP-4153242-B1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | SERVIER LAB (FR) | 2024-05-15 | — | — | EP | claimed |
| EP-4153242-A1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | Les Laboratoires Servier (FR) | 2023-03-29 | — | — | EP | claimed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-11 | — | — | US | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| CN-118950437-A | Photoelectric material based on ultrathin protein nano film, and preparation method and application thereof | 陕西师范大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118844429-A | Protein-based agricultural chemical with reduced and enhanced efficacy | 陕西师范大学 | 2024-10-29 | — | — | CN | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-4997822-A | Antitumor agents, treating AIDS | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1991-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | DPP7 1446/4885OTC 3716/4885DDAH1 992/4885 |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | DPP7 1936/4885OTC 4532/4885DDAH1 474/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | DPP7 1558/4885OTC 4746/4885DDAH1 2628/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | DPP7 1446/4885OTC 3716/4885DDAH1 992/4885 |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | CNTN1, BTN3A1, FABP6 | DPP7 49/4885OTC 2879/4885DDAH1 339/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | DPP7 1785/4885OTC 4383/4885DDAH1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.